Autobio Diagnostics (603658) Fundamentals 2026 — P/E 18.2x, Revenue Analysis | SniperIQ
Autobio Diagnostics (603658) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥18.7B, trading at ¥32.73 on the SHH. This SniperIQ fundamentals page covers Autobio Diagnostics's valuation (P/E 18.2x, P/B 2.0x), profitability (net margin 24.5%), revenue (¥4.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Autobio Diagnostics's market cap?
Autobio Diagnostics (603658) has a market capitalization of approximately ¥18.7B, trading at ¥32.73 on the SHH. Market cap moves with the live share price.
What is Autobio Diagnostics's P/E ratio?
Autobio Diagnostics's trailing twelve-month P/E ratio is 18.2x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Autobio Diagnostics?
Autobio Diagnostics runs a net profit margin of 24.5%, a gross margin of 64.3%, and an operating margin of 25.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Autobio Diagnostics generate?
Autobio Diagnostics reported revenue of ¥4.2B for fiscal year 2025, with net income of ¥1.1B and earnings per share (EPS) of 1.87. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Autobio Diagnostics pay a dividend?
Autobio Diagnostics offers a trailing dividend yield of about 4.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Autobio Diagnostics financially healthy?
Autobio Diagnostics carries a debt-to-equity ratio of 0.10x and a current ratio of 2.67x, with a market beta of 0.07. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Autobio Diagnostics a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Autobio Diagnostics (603658) the key facts are: market cap ¥18.7B, P/E 18.2x, revenue ¥4.2B, 52-week range 28.18-42.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Autobio Diagnostics's full fundamentals live
Get Autobio Diagnostics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.